About the Study Drug

Actor portrayal.

Lenacapavir has received approval in the United States as a twice-yearly injectable PrEP option to reduce the risk of getting HIV-1 in adults and adolescents who weigh at least 77 pounds. Lenacapavir is still under investigation in other populations.

To learn more about the ongoing studies of lenacapavir for treatment,
please visit the CAPELLA and CALIBRATE clinical trial sites.

CAPELLA Study

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

CAPELLA study info

CAPELLA clinicaltrials.gov

CALIBRATE Study

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV

CALIBRATE study info

CALIBRATE clinicaltrials.gov

Gilead Clinical Trials Website

Search for and learn about the active and ongoing clinical trials that we are running.

Gilead clinical trials